Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
HRMY.US
id: 969, Created by , Scout

Harmony (HRMY) Alleged Multi-faceted Fraud Case

  • In March, report was published alleging multiple violations related to one of Harmony’s drugs.
  • On it, $HRMY fell 25.8%, losing $626M+ of shareholder value.
  • Investors may have grounds to suspect Harmony of fraudulent practices.
On March 28, 2023, Scorpion Capital published a report alleging, among other things, that Harmony’s narcolepsy drug, Wakix, has “alarming toxicity,” “no efficacy,” is based on “sham patents,” and “scam clinical trials,” and has been “pushed via false advertising and a vast off-label and physician kickback scheme”.

On this news, $HRMY fell 25.8% and lost over $626 million of its market capitalization, seriously damaging shareholders.

Considering all the information, investors might have grounds to suspect that Harmony and its executives failed to timely disclose and eliminate fraudulent practices, which consequently led to their losses.

The case is already under investigation by at least one of the reputable law firms.
Alleged Offence
Misleading Statements
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
28 March 2023
Collecting participants…

Harmony Biosciences Holdings

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the Unit...

    Ticker
    HRMY.US
    ISIN
    US4131971040
    CIK
    1802665
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462